Role of TNF alpha inhibitors in Ankylosing Spondylitis

Speciality: Rheumatology

Description:

A warm welcome to all the medical professionals in this interesting session on Role of TNF alpha inhibitors in Ankylosing Spondylitis
Tumor necrosis factor-alpha (TNF-α) inhibitors have revolutionized the treatment of ankylosing spondylitis (AS), a chronic inflammatory disease primarily affecting the spine and sacroiliac joints. TNF-α inhibitors, such as infliximab, adalimumab, etanercept, golimumab, and certolizumab pegol, target and neutralize TNF-α, a key cytokine involved in the inflammatory processes of AS.
Clinical trials have consistently demonstrated the efficacy of TNF-α inhibitors in managing AS. These biologic agents significantly reduce inflammation, decrease pain and stiffness, and improve physical function and overall quality of life. Patients treated with TNF-α inhibitors often experience rapid and sustained relief from symptoms, which traditional nonsteroidal anti-inflammatory drugs (NSAIDs) alone cannot achieve.
This is particularly important in preventing long-term disability and improving the overall prognosis for patients with AS.
Therefore, get an overall knowledge of updated role of TNF alpha inhibitors in ankylosing spondylitis
 

See More Webinars @ Hidoc Webinars